Results of Sumavel DosePro Phase 4 Trial Announced
Zogenix, Inc., has announced results of a Phase 4 clinical study of its Sumavel DosePro sumatriptan needle-free delivery system for treatment of migraine.
Last week, pharmaceutical company Zogenix, Inc., announced publication of results of a Phase 4 clinical study of its Sumavel DosePro sumatriptan needle-free delivery system for treatment of migraine. The study results were published online in the journal Headache.
The study included 212 adult patients who had been diagnosed with migraine and had been receiving treatment with triptans but reported being less than very satisfied with the results. Each patient used Sumavel DosePro to treat between one and four migraines over a 60-day period. The study used the Patient Perception of Migraine Questionnaire-Revised to evaluate patient satisfaction.
The results: Overall satisfaction of patients increased, and scores for efficacy, functionality, and tolerability increased, while the score for ease of use decreased.
Sources
Zogenix Announces Publication of SUMAVEL(R) DosePro(R) Phase 4 Clinical Data [Press Release]
